AT2 has been discussed as a target to test its role in lipid metabolism, and recent pharmacological studies have explicitly suggested that AT2 activation inhibits adiposity and obesity. The gene discussed is AGTR2; the disease is obesity due to melanocortin 4 receptor deficiency.